Prevest Denpro Limited submitted the transcript of its FY26 Earnings Conference Call held on June 29, 2026, pursuant to SEBI Regulations 30 and 46. The call was chaired by Mrs. Namrata Modi, Whole-Time Director and CFO, in the absence of Chairman Mr. Atul Modi due to a medical emergency.

Financial Performance FY 2025-26

  • Revenue from operations increased by 13.9% to ₹71.81 crores from ₹63.03 crores in FY25.
  • Total income grew by 14.4% to ₹76.72 crores.
  • EBITDA increased by 13.3% to ₹29.62 crores.
  • Profit Before Tax (PBT) grew by 13.9% to ₹27.61 crores.
  • Profit After Tax (PAT) increased by 12.9% to ₹20.49 crores.
  • Margins: EBITDA margin at 38.6%, PBT margin at 36.0%, PAT margin at 26.7%.
  • Domestic business growth: 9%.
  • Export business growth: 17.58%.

Q4 FY 2025-26 Performance

  • Revenue from operations: ₹18.94 crores (up 2.63%).
  • Total income: ₹20.35 crores (up 4.18%).
  • EBITDA: ₹8.32 crores (up 9.09%).
  • PBT: ₹7.81 crores (up 9.21%).
  • PAT: ₹5.82 crores (up 13.23%).
  • Margins: EBITDA margin 40.87%, PBT margin 38.38%, PAT margin 28.61%.

Business and Strategic Updates

  • Established a wholly owned subsidiary in the UAE to strengthen regional presence. Commercial operations delayed due to geopolitical tensions in the Middle East.
  • Commenced commercialization of Disinfectant business, with encouraging initial customer response.
  • Advanced digital dentistry initiatives, including development of 3D printers through in-house R&D and global collaborations.
  • US market business (through Axiodent subsidiary and private labeling) grew 37.58% year-on-year.
  • Oradox Oral Care business faced challenges due to new US regulations (MoCRA) and Middle East conflicts, resulting in a 2% decline in sales.
  • Conducted 16 educational programs for dental professionals across restorative, endodontic, and digital dentistry portfolios.

Operational Details

  • Capacity utilization: Traditional capacity at 67-68% (potential turnover ₹125 crores at full capacity). New production lines (digital dentistry, resin, disinfectants) at 18-20% utilization.
  • R&D focus: Developed new products including caries removal agents, endodontic irrigants, self-etching resins, periodontal gels (at Technology Readiness Level 7). Working on import substitution of raw materials.
  • Distribution expansion in Tier 2 and Tier 3 cities, and strengthening of sales team.

Management Outlook

  • Focus on expanding digital dentistry, 3D resins, Rotoflex range, and disinfectants portfolio.
  • Plans to deepen export presence and enter new international markets.
  • Continue investment in next-generation dental materials and digital technologies.
  • Domestic market growth supported by increasing oral healthcare awareness and adoption of advanced technology.

Participants

Management: Mrs. Namrata Modi (Whole-Time Director and CFO), Dr. Sai Kalyan (Director of Research and Academics), Mr. Vaibhav Munjal (Chief Marketing Officer), Mr. Vinay Jamwal (Financial Advisor).